Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 97,116

Document Document Title
WO/2014/112676A1
The present invention relates to a massage oil for deep sleep in which a valerian oil, a lavender oil, and a chamomile roman oil are mixed. According to the present invention, the massage oil effectively treats insomnia and especially sh...  
WO/2014/111751A1
The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of narcolepsy, excessive daytime sleepiness, nocturnal sleep disruption and/o...  
WO/2014/111957A1
The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents wherein the drug or therapeutic agents contain at least one carboxylic acid group. The invention also relates to processes for the prep...  
WO/2014/113609A1
Stable indole-3-propionic acid salts of S-adenosyl-L-methionine, or a pharmaceutically acceptable salt thereof, are disclosed, as well as pharmaceutical compositions comprising the indole-3-propionic acid salts, methods of using the indo...  
WO/2014/112152A1
Provided is a medicine used as an external preparation for treatment of local symptoms of neuropathic disease, wherein gabapentine or pregabalin is contained in the form of an aqueous solution.  
WO/2014/113539A1
The present invention relates to the isolation of polypeptides derived from the Clostridium botulinum neurotoxin and the use thereof as treatment for neuronal injury such as spinal cord injury. Botulinum neurotoxin binds to neural cells ...  
WO/2014/111028A1
Disclosed in the present invention are a new genistein alkylamine compound (I) and pharmaceutically acceptable salts thereof, and the preparation method and use thereof in the preparation of drugs for the treatment and/or prevention of d...  
WO/2014/111496A1
The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, ...  
WO/2014/111004A1
Disclosed are a flavone alkylamine compound of formula (I), pharmaceutically acceptable salt and preparation method thereof, pharmaceutical composition, and uses thereof in the preparation of drugs for treating and/or preventing neurodeg...  
WO/2014/112492A1
[Problem] To provide novel compounds having agonist activity on dopamine D2 receptors. [Solution] Provided are compounds represented by general formula (I) (in the formula, R1 is a C1-6 alkyl or the like; R2 is a C1-6 alkyl, aralkyl, het...  
WO/2014/111356A1
The invention relates to the use of a compound of formula I wherein A1 is phenyl or a five or six membered hereroaryl group, containing 1, 2 or 3 heteroatoms, selected from N or S; R1 is hydrogen, lower alkyl, halogen, lower alkyl substi...  
WO/2014/113624A1
Amine chelates capable of antioxidant capacity and amyloid disaggregation are shown which may be useful in targeting metal-based oxidative stress in neurodegenerative disorders. Pyclen, a backbone commonly investigated for contrast agent...  
WO/2014/113359A1
The present invention provides an aqueous pharmaceutical composition comprising the fusion protein whose amino acid sequence is set forth as SEQ ID NO:1 and an aqueous solution comprising 40 to 60 mM sodium phosphate. The present inventi...  
WO/2014/111839A1
Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly α7 subtype, its tautomeric forms, its stereoisomers, its pharmace...  
WO/2014/112641A1
A nitric oxide (NO) concentration elevating agent containing glutathione or a salt thereof as an active ingredient, an NO concentration elevating agent containing glutathione or a salt thereof as an active ingredient for preventing or al...  
WO/2014/113822A1
Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiment...  
WO/2014/112145A1
The present invention mainly addresses the problem of providing a radical curing agent for a disease associated with neuroaxonal dysfunction (for example, Alzheimer's disease, dementia, Parkinson's disease, spinal cord injury, brain cont...  
WO/2014/107771A1
Substituted indazole or imidazole derivatives of formula I as in vitro selective and reversible MAO-B inhibitors and for use in the prevention and treatment of meurodegenerative disorders such as Parkinson's disease, Alzheimer's disase a...  
WO/2014/110154A1
Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune d...  
WO/2014/108520A1
The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein:R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R...  
WO/2014/110090A1
In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a)...  
WO/2014/110065A1
A dual H1 inverse agonist/5-HT2A receptor antagonist of the formula: [Formula I], its uses, and methods for its preparation are described.  
WO/2014/109725A3
The present invention provides a prophylactic or therapeutic agent for depression (including each subtype according to DSM-IV of depression) or anxiety by increasing the levels of serotonin in the brain comprising administration of glycy...  
WO/2014/110185A1
Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase white matter remodeling, neurite outgrowth, or neurological function in a patient in need thereof. Some embodiments also comprise the admini...  
WO/2014/109524A1
The present invention relates to a composition for protecting nerve cells, a composition for preventing or treating nerve disorders, and a health functional food for preventing or improving nerve disorders, which comprise thymoquinone an...  
WO/2014/108475A1
The present invention relates to an isolated peptide for use in the treatment of cancer consisting of 12 to 50 amino acid residues comprising - at least two beta-strands, or - at least two alpha-helices or - at least one beta-strand and ...  
WO/2014/110259A1
The present invention relates to solid state forms of JAK inhibitor (R)-2-(2-(lH-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino) -2-methyl-N-(2,2,2-trifluoroethyl)butanamide (Compound 1) including solvates, salts, co-crystals, and an amo...  
WO/2014/108168A1
The present invention provides compounds of Formula (I) for the treatment of parasitic diseases including malaria, as well as neurodegenerative diseases. Formula (I) wherein R3, R4, X and Y have the meaning given in claim 1.  
WO/2014/108899A1
The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.  
WO/2014/110234A1
The invention relates to the use of scyllo-inositol in treating personality disorders, in particular social withdrawal, as well as pharmaceutical compositions comprising effective amounts of scyllo-inositol for treating such disorders.  
WO/2014/108514A1
Disclosed herein is a novel and stable salt of tapentadol, tapentadol maleate, its polymorphic Forms as well as processes for its preparation, pharmaceutical compositions, and preparation thereof.  
WO/2014/107794A1
The presently disclosed invention and particular invention embodiments relate to formulations, methods, procedures, and combinations thereof for treating numerous types of trauma-induced and other neurological disorders and injuries, suc...  
WO/2014/109414A1
A compound represented by general formula [1] or a salt thereof. (In general formula [1], Z1 represents a group such as N or CH; X1 represents a group such as NH; R1 represents a group such as a heteroaryl group; R2, R3, and R4 represent...  
WO/2014/109296A1
Disclosed is a compound represented by formula (1) or a salt thereof. In formula (1): X represents a residue of a compound having an activity to bind to at least one member selected from the group consisting of amyloid β protein, a tau ...  
WO/2014/110103A1
The present invention relates to compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, that modulate the activity of the histamine H3 receptor (Ia). Compounds of the present invention and pharma...  
WO/2014/106861A1
The present, invention relates to novel the (4E)-4-(4-substituted benzylideneamino)- 2,3-dihydro-3-substituted -2-thioxothiazole-5-carbonitriles of general formula A and a process for the preparation thereof. The compounds of present inv...  
WO/2014/106660A1
The present invention relates to benzodioxane-piperidine derivatives corresponding to general formula I: in which in particular: -R1 is one or more identical or different substituent(s) on the benzene ring, each being independently a hyd...  
WO/2014/107686A1
This invention relates to the use of geranylgeranyl acetone (GGA), its isomers, and GGA derivatives in a method for for treating a disease in a subject mediated in part by miRNA-378 or miRNA-711 increased activity comprising administerin...  
WO/2014/106612A1
The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.  
WO/2014/106622A1
The present invention relates to new 1,2,3-triazole-amine derivatives of formula (I), having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising the...  
WO/2014/106988A1
The present invention relates to a method for protecting nerve cells from nerve cell death induced by kainic acid by pretreating nerve cells with anthocyanin, and to a composition comprising anthocyanin, as an active ingredient, for prot...  
WO/2014/103801A1
[Problem] To provide an OCT3 activity inhibitor having a different basic skeleton than that of conventional OCT3 activity inhibitors. [Solution] This inhibitor of organic cation transporter 3 (OCT3) contains, as an active component, an i...  
WO/2014/103475A1
The purpose of the present invention is to provide a skin-exterior anti-ageing composition for preventing or improving trouble areas upon the exterior of the skin caused by ageing and degradation such as wrinkles, fine lines, blotches, a...  
WO/2014/102417A1
The invention relates to a use of a compound of formula (I), or one of the salts thereof, wherein: R represents a linear or branched aliphatic chain selected from the group consisting of a C1-C16 saturated hydrocarbonated chain and a C2-...  
WO/2014/104171A1
The purpose of the present invention is to provide a skin-exterior anti-ageing composition for preventing or improving trouble areas upon the exterior of the skin caused by ageing and degradation such as wrinkles, fine lines, blotches, a...  
WO/2014/103481A1
Provided is a novel compound which has excellent Aβ aggregation inhibitory activity and is useful as a pharmaceutical product. A cyclic peptide comprising the amino acid sequence represented by formula (1), wherein an α-amino group at ...  
WO/2014/104757A1
The present invention relates to a compound selected from the group consisting of a compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, an ester, a prodrug, a hydrate, a solvate, and an isomer thereof,...  
WO/2014/100934A1
The compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds are provided. The methods of treating disea...  
WO/2014/105666A1
Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the...  
WO/2014/104220A1
The objective of the present invention is to provide a method for preventing denaturation by oxygen of drugs inside a patch that is enclosed in a packaging container. The present invention is a packaging comprising a packaging container ...  

Matches 301 - 350 out of 97,116